All potential drugs go through rigorous safety assessments during their development – and so do their names. Selecting a drug name can take years.
See how in our interactive.
GSK CEO Emma Walmsley may be vacating her post this year, but she’s still steering the large pharma through some of its thorniest challenges.
On the heels of Pfizer’s agreement with the Trump administration to lower drug prices, Walmsley said GSK is also in dealmaking mode with the White House.
“The U.S. is by far the biggest priority market for our industry because the U.S. is the best country in the world to discover and develop innovation,” she said at a Bloomberg conference.
Come January, GSK’s relationship with the U.S. will be in the hands of incoming CEO Luke Miels, who’s been climbing pharma’s corporate ladder since he got his start in sales and marketing at AstraZeneca in the 1990s. And Walmsley’s departure will contribute to a dearth of women who hold the CEO position at pharma’s largest companies. Today, we’re looking at who will be the industry’s top woman CEOs once Walmsley waves goodbye.
In February, the U.S. government put forward its initial price proposals on 10 top-selling medicines, kicking off negotiations that will run through September. Explore drug pricing developments in this Trendline.
Since 2022, Chinese companies account for 31% of the total global drug market. Learn how Western pharma companies can collaborate with China’s booming bioscience sector in this playbook.
